Biocept (NASDAQ:BIOC) Trading 5.8% Higher

Biocept Inc (NASDAQ:BIOC)’s share price traded up 5.8% during trading on Thursday . The company traded as high as $0.58 and last traded at $0.55, 1,461,900 shares were traded during mid-day trading. A decline of 32% from the average session volume of 2,151,965 shares. The stock had previously closed at $0.52.

Separately, ValuEngine upgraded Biocept from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.

The business has a fifty day moving average price of $0.73 and a two-hundred day moving average price of $0.93. The company has a quick ratio of 1.71, a current ratio of 1.83 and a debt-to-equity ratio of 0.13.

Biocept (NASDAQ:BIOC) last announced its quarterly earnings data on Wednesday, November 13th. The medical research company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The business had revenue of $1.53 million for the quarter. Biocept had a negative return on equity of 268.76% and a negative net margin of 552.54%.

An institutional investor recently raised its position in Biocept stock. Vanguard Group Inc. grew its position in Biocept Inc (NASDAQ:BIOC) by 107.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 155,963 shares of the medical research company’s stock after purchasing an additional 80,756 shares during the period. Vanguard Group Inc. owned approximately 0.83% of Biocept worth $173,000 at the end of the most recent quarter. Institutional investors and hedge funds own 1.60% of the company’s stock.

Biocept Company Profile (NASDAQ:BIOC)

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Story: Using other technical indicators with support levels

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit